Article Text

other Versions

PDF
Idiopathic Thrombocytopenic Purpura and the second dose of MMR
  1. Julia Stowe (julia.stowe{at}hpa.org.uk)
  1. HPA, United Kingdom
    1. George Kafatos (george.kafatos{at}hpa.org.uk)
    1. Health Protection Agency, United Kingdom
      1. Nicholas J Andrews (nick.andrews{at}hpa.org.uk)
      1. HPA, United Kingdom
        1. Elizabeth Miller (liz.miller{at}hpa.org.uk)
        1. Health Protection Agency, United Kingdom

          Abstract

          An increase in idiopathic thrombocytopenic purpura (ITP) cases in the 6 weeks following the first dose of the measles, mumps and rubella (MMR) vaccine has been established, with absolute risks estimated as 1 in 22,300 (1) and 1 in 21,000 vaccine doses (2), and two in every three cases being vaccine-attributable.

          However, the risk after a second dose of MMR vaccine has not been investigated.

          • idiopathic thrombocytopenic purpura
          • measles, mumps and rubella
          • vaccine safety

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.